Related Experiment Video
Updated: Jun 28, 2026

Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis
Published on: June 3, 2016
Glucocorticoid-induced apoptosis requires FOXO3A activity
Jiexian Ma1, Yanhui Xie, Yi Shi
1The Hematology Department of Huashan Hospital Affiliated in Fudan University, Shanghai 200040, China.
Abstract:
Dexamethasone (DEX) induces apoptosis in lymphocytes, while protecting some cancer cells from apoptosis, by a poorly understood mechanism. In this study, we examined the potential role of the forkhead transcription factor (FOXO3A) in DEX-induced apoptosis. Unphosphorylated FOXO3A, the active form of FOXO3A, can translocate into nucleus and induce apoptosis. In lymphocytes, FOXO3A is upregulated by DEX treatment, while phospho-FOXO3A was downregulated. In several different types of cancer cells, we found that sensitivity to DEX correlated negatively to expression of phospho-FOXO3A. We conclude that DEX might maintain FOXO3A in its unphosphorylated, active form. Knockdown of FOXO3A expression using a small interfering RNA (siRNA) significantly reduces apoptosis in lymphocytes. This study suggests that FOXO3A has a pivotal role in DEX-induced apoptosis. Increased phospho-FOXO3A levels in cancer cells may explain, in part, their resistance to apoptosis. Therefore, FOXO3A may be a potential target for cancer therapy.
Insights
Dexamethasone (DEX) triggers apoptosis in lymphocytes by activating the FOXO3A transcription factor. Cancer cells resist DEX-induced apoptosis, potentially due to higher levels of phosphorylated FOXO3A.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- Dexamethasone (DEX) is known to induce apoptosis in lymphocytes and protect certain cancer cells.
- The precise molecular mechanisms underlying DEX's effects on apoptosis remain incompletely understood.
- The forkhead transcription factor FOXO3A plays a role in regulating apoptosis.
Purpose of the Study:
- To investigate the role of FOXO3A in dexamethasone (DEX)-induced apoptosis.
- To explore the differential regulation of FOXO3A activity in lymphocytes versus cancer cells following DEX treatment.
Main Methods:
- Examined FOXO3A expression and phosphorylation status in lymphocytes and cancer cells after DEX treatment.
- Utilized small interfering RNA (siRNA) to knock down FOXO3A expression in lymphocytes.
- Correlated DEX sensitivity with phospho-FOXO3A levels in various cancer cell lines.
Main Results:
- DEX treatment upregulated total FOXO3A and downregulated phospho-FOXO3A in lymphocytes, indicating activation of the unphosphorylated form.
- Sensitivity to DEX in cancer cells negatively correlated with the expression of phospho-FOXO3A.
- Knockdown of FOXO3A significantly reduced DEX-induced apoptosis in lymphocytes.
Conclusions:
- FOXO3A is a key mediator of DEX-induced apoptosis in lymphocytes.
- DEX appears to promote apoptosis by maintaining FOXO3A in its active, unphosphorylated state.
- Elevated phospho-FOXO3A levels in cancer cells may contribute to their resistance to DEX, suggesting FOXO3A as a potential therapeutic target.
Related Concept Videos
The Extrinsic Apoptotic Pathway
Apoptosis
Caspases
The Intrinsic Apoptotic Pathway
Cellular Injury V: Apoptosis and Autophagy
TGF - β Signaling Pathway
